J&J Likely To Post Solid Q4 Led By Ramp Up In Oncology Drug Sales

Johnson & Johnson is set to report its Q4 2017 earnings on January 23, and we expect the company to post solid numbers, primarily led by continued growth in oncology drug sales, which saw growth of 25% in the previous quarter.